Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Pfizer Ltd. Regulatory Filings 2024

Sep 23, 2024

60507_rns_2024-09-23_e8c12dd1-68cd-4b3b-9b85-6366aefa2c49.pdf

Regulatory Filings

Open in viewer

Opens in your device viewer

==> picture [100 x 41] intentionally omitted <==

Pfizer Limited

The Capital, 1802/1901, Plot No. C - 70, G Block, Bandra Kurla Complex, Bandra (East), Mumbai 400 051. Tel : +91 22 6693 2000 Fax : +91 22 2654 0274

September 23, 2024

To, Mr. Amit Shinde, Chief Manager, Surveillance The National Stock Exchange of India Ltd. Exchange Plaza, 5th Floor, Plot No. C/1, G Block Bandra-Kurla Complex, Bandra (E) Mumbai – 400 051 Scrip Symbol: PFIZER

Dear Sir,

Sub.: Increase in Volume

We refer to your letter No. NSE/CM/Surveillance/14773 dated September 20, 2024, on the subject, received by us via email on Friday, September 20, 2024 at 6.02 p.m.

At the outset, we would like to inform you that the Company has been strictly adhering to all the disclosure requirements in terms of Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015 (“LODR”) and will continue to adhere to all the compliance requirements.

You have requested us to provide you with any information/announcement that may have a bearing on the price/volume behavior in Pfizer Limited's scrip. Please be informed that, in our opinion, there is no undisclosed/unpublished price sensitive information which may have a bearing on the price/volume behaviour of our scrip. Consequently, we would not like to speculate nor comment on the price/volume behaviour of Pfizer Limited's scrip in the past.

We assure you that, if and when Pfizer Limited makes any announcement regarding any material development in respect of our business or whenever there is any material development requiring intimation under SEBI LODR, we will ensure that we continue to follow the mandated procedure of informing Stock Exchanges in a timely manner, so as to ensure uniform and simultaneous disclosure to all the investors.

We trust the above clarifies the matter.

Yours truly,

For Pfizer Limited

==> picture [87 x 50] intentionally omitted <==

Prajeet Nair Director – Corporate Services & Company Secretary

CIN: L24231MH1950PLC008311 Email ID: [email protected] Website: www.pfizerltd.co.in